Drug developers at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
75 drug developers are at ESMO 2026 — 59 presentations on the program and 74 with a booth in the exhibit hall. Most represented: AstraZeneca (1 on the program), GSK (1 on the program), Avacta (1 on the program). 74 of them have their own page in this guide. As of Sep 29, 2026.
Tumour type
Top represented
Showing 1–9 of 75 organizations
| Organization | ESMO 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company with a large oncology portfolio including osimertinib, durvalumab, olaparib and trastuzumab deruxtecan. | Booth Exhibiting at Booth 8066 Talk Fri Oct 23 13:30 Satellite Fri Oct 23 18:15–19:45 AstraZeneca - Advancing excellence in lung cancer: New biomarkers, novel combinations, and changing standards of care Lung & thoracic cancersBiomarkers & precision oncology Satellite Sat Oct 24 13:00–14:30 Satellite Sun Oct 25 10:15–11:45 AstraZeneca - On the frontlines: Optimizing ADC patient care in lung cancer Lung & thoracic cancersNursing & supportive care Satellite Sun Oct 25 12:00–13:00 Daiichi Sankyo | AstraZeneca - Piecing together the ADC patient journey: The vital role of nurses in advanced breast cancer care Breast cancerNursing & supportive care Satellite Mon Oct 26 13:00–14:30 AstraZeneca - Advancing clinical practice and patient care in gastroesophageal cancer Gastrointestinal cancers |
British pharmaceutical company whose oncology medicines include niraparib, dostarlimab and momelotinib. | Booth Exhibiting at Booth 1023 Satellite Fri Oct 23 18:15–19:45 Satellite Sat Oct 24 13:00–14:30 GSK - From Discovery to Impact: ADCs in Endometrial and Ovarian Cancer Care Gynaecological cancers Talk Mon Oct 26 10:55–11:15 |
Avacta London, United Kingdom | |
UK biotech developing pre|CISION tumour-activated peptide drug conjugates. | Satellite Sat Oct 24 10:20–10:40 |
Global pharmaceutical company, known as Merck & Co. in the US and Canada, whose oncology medicines include pembrolizumab. | Booth Exhibiting at Booth 8030 Satellite Fri Oct 23 09:45–11:15 MSD - Emerging Evidence and Treatment Integration in Ovarian and Endometrial Cancer Gynaecological cancersBiomarkers & precision oncology Satellite Sat Oct 24 12:00–13:30 Satellite Sat Oct 24 13:00–14:30 MSD - Practical MDT Considerations for the new Treatment Paradigm in Resectable LA HNSCC Sarcoma, CNS, head & neck and rare cancers Satellite Sun Oct 25 18:30–20:00 MSD - Is the precision medicine ecosystem ready? Overcoming diagnostic barriers in oncology Biomarkers & precision oncology Satellite Mon Oct 26 13:00–14:30 Daiichi Sankyo and MSD - Shaping the Future of ES-SCLC: Pioneering Treatment Strategies Lung & thoracic cancers Satellite Mon Oct 26 13:00–14:30 |
Daiichi Sankyo Tokyo, Japan | |
Japanese pharmaceutical company developing antibody-drug conjugates including trastuzumab deruxtecan and datopotamab deruxtecan. | Booth Exhibiting at Booth 8033 Satellite Sun Oct 25 12:00–13:00 Daiichi Sankyo | AstraZeneca - Piecing together the ADC patient journey: The vital role of nurses in advanced breast cancer care Breast cancerNursing & supportive care Satellite Sun Oct 25 18:30–20:00 Daiichi Sankyo - Patient Identification in NSCLC: 10 From Actionable Genomic Alterations to Emerging ADC Opportunities Lung & thoracic cancersBiomarkers & precision oncology Satellite Mon Oct 26 13:00–14:30 Daiichi Sankyo and MSD - Shaping the Future of ES-SCLC: Pioneering Treatment Strategies Lung & thoracic cancers |
Global pharmaceutical company whose oncology medicines include abemaciclib, selpercatinib and pirtobrutinib. | Booth Exhibiting at Booth 1058 Satellite Sat Oct 24 13:00–14:30 Satellite Sat Oct 24 18:30–20:00 Satellite Sun Oct 25 13:15–14:45 |
Healthcare company whose Innovative Medicine business markets oncology drugs including amivantamab, daratumumab and teclistamab. | Booth Exhibiting at Booth 1029 Satellite Fri Oct 23 18:15–19:45 Satellite Sat Oct 24 14:00–15:30 J&J - Collaborative Precision Care in EGFR-mutated NSCLC. A Multidisciplinary Approach Lung & thoracic cancersNursing & supportive care Satellite Sun Oct 25 13:00–14:30 Johnson & Johnson - Transforming the Treatment Journey in EGFR- Mutant NSCLC Lung & thoracic cancers |
Global pharmaceutical company whose oncology portfolio spans breast, lung, prostate, bladder and blood cancers, including antibody-drug conjugates from its Seagen acquisition. | Booth Exhibiting at Booth 8031 Satellite Sat Oct 24 13:00–14:30 Satellite Sat Oct 24 18:30–20:00 Pfizer - Breaking the Treatment Plateau in Advanced NSCLC: Antibody Therapy Redefined Lung & thoracic cancers Satellite Sun Oct 25 18:30–20:00 |
US biotechnology company whose cancer medicines include the PD-1 antibody cemiplimab and bispecific antibodies for blood cancers. | Booth Exhibiting at Booth 1017 Satellite Sun Oct 25 13:00–14:30 Satellite Sun Oct 25 18:30–20:00 Satellite Sun Oct 25 18:30–20:00 Regeneron - Perspectives on Early-stage Melanoma: Diagnosis, Staging, and Treatment Melanoma & skin cancers |
Instantly find 20 buyers from drug developers
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ESMO 2026 by
Organization type
Tumour type
Exhibit hall
Everyone
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction